Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning

Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:July 21, 2016
End Date:February 2019
Contact:Bryan Traughber, MD

Use our guide to learn which trials are right for you!

This clinical research study tests the Uronav system. Patients with prostate cancer will be
asked to take part in this study.

Uronav system is an investigational device that is used on this study to help place markers
in the patient. These are called fiducial markers and they are placed in the patient to help
plan radiation treatment. Radiation therapy treatment will be planned by the treating
physician and will not be experimental or part of this research study.

This study will also test the similarities and differences of biopsy tissue structures and
the findings from the intraprostatic MRI (internally guided MRI).

Study Objectives

Specific Aim 1: Evaluate final pathology post-operatively for histopathology confirmation of
multiparametric MRI targets detected during treatment planning. This will be accomplished by
using transperineal biopsies obtained prior to interstitial brachytherapy during the
procedure, while under anesthetic just prior to the placement of the brachytherapy needles
and sources.

Specific Aim 2: Evaluate the ability of the Uronav system in a transperineal setting to guide
biopsy needle placement using the electromagnetic guidance system and transperineal
ultrasound probe stabilization device and stepper.

Inclusion Criteria:

- Patients must have histopathology confirmed prostate cancer that is Gleason score
≤7(4+3) clinical stage ≤ T2bN0M0 with a Prostate-specific antigen (PSA) below 15

- Patients must have MRI findings reporting intraprostatic lesions suspicious for

- Patient must not have had any prior treatment for prostate cancer

- Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2

- Subjects must have an International Prostate Symptom Score of ≤ 15.

- Subjects must have the ability to understand and the willingness to sign a written
informed consent document.

Exclusion Criteria:

- Gleason score of ≥ 8(4+4)

- PSA ≥ 15 ng/mL.

- Clinical stage >T2b or evidence of nodal

- Patients who are on anticoagulants or high dose aspirin therapy that cannot be safely
stopped for greater than 10 days prior to treatment should be excluded to limit
increased risk for urinary obstruction.

- Patients with uncontrolled intercurrent illness including, but not limited to ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements.

- HIV-positive patients on combination antiretroviral therapy are ineligible because of
the unlikely risk of prostate cancer being life threatening in this population.
We found this trial at
11100 Euclid Avenue
Cleveland, Ohio 44106
Principal Investigator: Bryan Traughber, MD
Phone: 216-844-3100
Case Comprehensive Cancer Center The Case Comprehensive Cancer Center (Case CCC) based at Case Western...
Cleveland, OH
Click here to add this to my saved trials